Teva Pharmaceutical Industries (TEVA) Receives New Coverage from Analysts at Guggenheim

Analysts at Guggenheim initiated coverage on shares of Teva Pharmaceutical Industries (NYSE:TEVA) in a research report issued to clients and investors on Tuesday, MarketBeat reports. The brokerage set a “neutral” rating and a $16.00 price target on the stock. Guggenheim’s price objective would indicate a potential downside of 14.02% from the stock’s current price.

Other equities research analysts also recently issued research reports about the stock. BidaskClub downgraded shares of Teva Pharmaceutical Industries from a “sell” rating to a “strong sell” rating in a research note on Wednesday, August 16th. Citigroup downgraded shares of Teva Pharmaceutical Industries from a “buy” rating to a “neutral” rating and lowered their target price for the company from $32.00 to $19.00 in a research note on Wednesday, August 16th. Cantor Fitzgerald set a $17.00 price target on shares of Teva Pharmaceutical Industries and gave the company a “hold” rating in a report on Monday, September 11th. Royal Bank of Canada upped their price target on shares of Teva Pharmaceutical Industries from $8.00 to $13.00 and gave the company an “underperform” rating in a report on Sunday, November 5th. Finally, Oppenheimer reiterated a “hold” rating on shares of Teva Pharmaceutical Industries in a report on Monday, September 11th. Five research analysts have rated the stock with a sell rating, nineteen have assigned a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $20.65.

Shares of Teva Pharmaceutical Industries (NYSE TEVA) traded up $1.31 during trading hours on Tuesday, reaching $18.61. 66,141,613 shares of the company’s stock traded hands, compared to its average volume of 26,438,098. Teva Pharmaceutical Industries has a 1 year low of $10.85 and a 1 year high of $38.31. The company has a debt-to-equity ratio of 1.20, a current ratio of 0.96 and a quick ratio of 0.66. The company has a market capitalization of $18,907.76, a P/E ratio of 4.30 and a beta of 0.55.

A number of hedge funds have recently made changes to their positions in the business. San Francisco Sentry Investment Group CA bought a new position in shares of Teva Pharmaceutical Industries in the second quarter valued at about $106,000. Bronfman E.L. Rothschild L.P. raised its position in shares of Teva Pharmaceutical Industries by 2.6% in the second quarter. Bronfman E.L. Rothschild L.P. now owns 3,711 shares of the company’s stock valued at $123,000 after purchasing an additional 94 shares during the period. Shelter Mutual Insurance Co bought a new position in shares of Teva Pharmaceutical Industries in the second quarter valued at about $133,000. Fayez Sarofim & Co. bought a new position in shares of Teva Pharmaceutical Industries in the second quarter valued at about $204,000. Finally, Taurus Asset Management LLC bought a new position in shares of Teva Pharmaceutical Industries in the second quarter valued at about $206,000. Hedge funds and other institutional investors own 52.05% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This news story was first reported by American Banking News and is owned by of American Banking News. If you are reading this news story on another site, it was copied illegally and reposted in violation of US and international trademark and copyright law. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2017/12/17/teva-pharmaceutical-industries-teva-receives-new-coverage-from-analysts-at-guggenheim.html.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Analyst Recommendations for Teva Pharmaceutical Industries (NYSE:TEVA)



Leave a Reply